메뉴 건너뛰기




Volumn 63, Issue 3, 2011, Pages 573-586

American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(44)  Felson, David T a,b   Smolen, Josef S c   Wells, George d   Zhang, Bin a   Van Tuyl, Lilian H D e   Funovits, Julia c   Aletaha, Daniel c   Allaart, Cornelia F f   Bathon, Joan g,h   Bombardieri, Stefano i   Brooks, Peter j   Brown, Andrew k   Matucci Cerinic, Marco l   Choi, Hyon d   Combe, Bernard m   De Wit, Maarten n   Dougados, Maxime o   Emery, Paul p   Furst, Daniel q   Gomez Reino, Juan r   more..


Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 79953752083     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30129     Document Type: Article
Times cited : (663)

References (68)
  • 1
    • 0028866438 scopus 로고
    • Early rheumatoid arthritis: Time to aim for remission?
    • Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
    • (1995) Ann Rheum Dis , vol.54 , pp. 944-947
    • Emery, P.1    Salmon, M.2
  • 2
    • 66249139579 scopus 로고    scopus 로고
    • Defining remission in rheumatoid arthritis: Results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference
    • Van Tuyl LH, Vlad SC, Felson DT, Wells G, Boers M. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. Arthritis Rheum 2009;61:704-10.
    • (2009) Arthritis Rheum , vol.61 , pp. 704-710
    • Van Tuyl, L.H.1    Vlad, S.C.2    Felson, D.T.3    Wells, G.4    Boers, M.5
  • 3
    • 33750699312 scopus 로고    scopus 로고
    • What should be our treatment goal in rheumatoid arthritis today?
    • Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006;24:S-7-13. (Pubitemid 44696862)
    • (2006) Clinical and Experimental Rheumatology , vol.24 , Issue.6 SUPPL. 43
    • Smolen, J.S.1    Aletaha, D.2
  • 5
    • 48149100741 scopus 로고    scopus 로고
    • Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double-blind, parallel treatment trial
    • Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
    • (2008) Lancet , vol.372 , pp. 375-382
    • Emery, P.1    Breedveld, F.C.2    Hall, S.3    Durez, P.4    Chang, D.J.5    Robertson, D.6
  • 6
    • 38649098475 scopus 로고    scopus 로고
    • Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study
    • DOI 10.1002/art.23247
    • Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2007;59:32-41. (Pubitemid 351171876)
    • (2008) Arthritis Care and Research , vol.59 , Issue.1 , pp. 32-41
    • Burmester, G.R.1    Ferraccioli, G.2    Flipo, R.-M.3    Monteagudo-Saez, I.4    Unnebrink, K.5    Kary, S.6    Kupper, H.7
  • 7
    • 35648991026 scopus 로고    scopus 로고
    • Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
    • DOI 10.1136/ard.2007.071092
    • Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al, for the Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9. (Pubitemid 350032650)
    • (2007) Annals of the Rheumatic Diseases , vol.66 , Issue.11 , pp. 1443-1449
    • Verstappen, S.M.M.1    Jacobs, J.W.G.2    Van Der Veen, M.J.3    Heurkens, A.H.M.4    Schenk, Y.5    Ter Borg, E.J.6    Blaauw, A.A.M.7    Bijlsma, J.W.J.8
  • 8
    • 19944431840 scopus 로고    scopus 로고
    • Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial
    • DOI 10.1002/art.20712
    • Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35. (Pubitemid 40129229)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.1 , pp. 27-35
    • Quinn, M.A.1    Conaghan, P.G.2    O'Connor, P.J.3    Karim, Z.4    Greenstein, A.5    Brown, A.6    Brown, C.7    Fraser, A.8    Jarret, S.9    Emery, P.10
  • 9
    • 33846001961 scopus 로고    scopus 로고
    • EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    • Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld FC, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;66: 34-45.
    • (2006) Ann Rheum Dis , vol.66 , pp. 34-45
    • Combe, B.1    Landewe, R.2    Lukas, C.3    Bolosiu, H.D.4    Breedveld, F.C.5    Dougados, M.6
  • 10
    • 77950307115 scopus 로고    scopus 로고
    • Treating rheumatoid arthritis to target: Recommendations of an international task force
    • for the T2T Expert Committee
    • Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al, for the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
    • (2010) Ann Rheum Dis , vol.69 , pp. 631-637
    • Smolen, J.S.1    Aletaha, D.2    Bijlsma, J.W.3    Breedveld, F.C.4    Boumpas, D.5    Burmester, G.6
  • 11
    • 34247568912 scopus 로고    scopus 로고
    • Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort
    • DOI 10.1002/art.22619
    • Khanna D, Oh M, Furst DE, Ranganath V, Gold RH, Sharp JT, et al, for the Western Consortium of Practicing Rheumatologists. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007;57:440-7. (Pubitemid 46682531)
    • (2007) Arthritis Care and Research , vol.57 , Issue.3 , pp. 440-447
    • Khanna, D.1    Oh, M.2    Furst, D.E.3    Ranganath, V.4    Gold, R.H.5    Sharp, J.T.6    Park, G.S.7    Keystone, E.C.8    Paulus, H.E.9
  • 12
    • 70350554084 scopus 로고    scopus 로고
    • Clinical and functional remission: Even though biologics are superior to conventional DMARDs overall success rates remain low - Results from RABBIT, the German biologics register
    • Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
    • (2006) Arthritis Res Ther , vol.8
    • Listing, J.1    Strangfeld, A.2    Rau, R.3    Kekow, J.4    Gromnica-Ihle, E.5    Klopsch, T.6
  • 14
    • 51849089097 scopus 로고    scopus 로고
    • Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries
    • for the Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis Group
    • Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Luukkainen RK, et al, for the Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008;58:2642-51.
    • (2008) Arthritis Rheum , vol.58 , pp. 2642-2651
    • Sokka, T.1    Hetland, M.L.2    Makinen, H.3    Kautiainen, H.4    Horslev-Petersen, K.5    Luukkainen, R.K.6
  • 16
    • 0019407824 scopus 로고
    • Preliminary criteria for clinical remission in rheumatoid arthritis
    • DOI 10.1002/art.1780241012
    • Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15. (Pubitemid 11022943)
    • (1981) Arthritis and Rheumatism , vol.24 , Issue.10 , pp. 1308-1315
    • Pinals, R.S.1    Masi, A.T.2    Larsen, R.A.3
  • 17
    • 0027936586 scopus 로고
    • World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials
    • Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:86-9. (Pubitemid 24285550)
    • (1994) Journal of Rheumatology , vol.21 , Issue.SUPPL. 41 , pp. 86-89
    • Boers, M.1    Tugwell, P.2    Felson, D.T.3    Van Riel, P.L.C.M.4    Kirwan, J.R.5    Edmonds, J.P.6    Smolen, J.S.7    Khaltaev, N.8    Muirden, K.D.9
  • 18
    • 5444231338 scopus 로고    scopus 로고
    • Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria
    • DOI 10.1093/rheumatology/keh297
    • Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5. (Pubitemid 39359299)
    • (2004) Rheumatology , vol.43 , Issue.10 , pp. 1252-1255
    • Fransen, J.1    Creemers, M.C.W.2    Van Riel, P.L.C.M.3
  • 19
    • 25444481274 scopus 로고    scopus 로고
    • Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states
    • DOI 10.1002/art.21235
    • Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52: 2625-36. (Pubitemid 41369090)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.9 , pp. 2625-2636
    • Aletaha, D.1    Ward, M.M.2    Machold, K.P.3    Nell, V.P.K.4    Stamm, T.5    Smolen, J.S.6
  • 20
    • 0029906505 scopus 로고    scopus 로고
    • Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score
    • Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
    • (1996) Br J Rheumatol , vol.35 , pp. 1101-1105
    • Prevoo, M.L.1    Van Gestel, A.M.2    Van 'T Hof, M.A.3    Van Rijswijk, M.H.4    Van De Putte, L.B.5    Van Riel, P.L.6
  • 21
    • 0028815803 scopus 로고
    • Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
    • Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
    • (1995) Arthritis Rheum , vol.38 , pp. 44-48
    • Prevoo, M.L.1    Van 'T Hof, M.A.2    Kuper, H.H.3    Van Leeuwen, M.A.4    Van De Putte, L.B.5    Van Riel, P.L.6
  • 23
    • 27744532112 scopus 로고    scopus 로고
    • Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
    • DOI 10.1136/ard.2005.037333
    • Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005;64:1410-3. (Pubitemid 41623849)
    • (2005) Annals of the Rheumatic Diseases , vol.64 , Issue.10 , pp. 1410-1413
    • Makinen, H.1    Kautiainen, H.2    Hannonen, P.3    Sokka, T.4
  • 24
    • 33646246737 scopus 로고    scopus 로고
    • Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: A comparison with the original das remission
    • Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.
    • (2006) Ann Rheum Dis , vol.65 , pp. 637-641
    • Landewe, R.1    Van Der Heijde, D.2    Van Der Linden, S.3    Boers, M.4
  • 25
    • 0029044362 scopus 로고
    • American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
    • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
    • (1995) Arthritis Rheum , vol.38 , pp. 727-735
    • Felson, D.T.1    Anderson, J.J.2    Boers, M.3    Bombardier, C.4    Furst, D.5    Goldsmith, C.6
  • 26
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial [published erratum appears in Ann Rheum Dis 2009,68:296]
    • Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [published erratum appears in Ann Rheum Dis 2009;68:296]. Ann Rheum Dis 2008;67:1516-23.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3    Cantagrel, A.4    Van Vollenhoven, R.5    Sanchez, A.6
  • 27
    • 67650379733 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374:210-21.
    • (2009) Lancet , vol.374 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3    Landewe, R.4    Matteson, E.L.5    Wollenhaupt, J.6
  • 28
    • 40749114497 scopus 로고    scopus 로고
    • Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    • DOI 10.1016/S0140-6736(08)60453-5, PII S0140673608604535
    • Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
    • (2008) The Lancet , vol.371 , Issue.9617 , pp. 987-997
    • Smolen, J.S.1    Beaulieu, A.2    Rubbert-Roth, A.3    Ramos-Remus, C.4    Rovensky, J.5    Alecock, E.6    Woodworth, T.7    Alten, R.8
  • 30
    • 74549137918 scopus 로고    scopus 로고
    • Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review
    • for the American College of Rheumatology and the European League Against Rheumatism Committee to Define Remission for Clinical Trials
    • Van Tuyl LH, Felson DT, Wells G, Smolen J, Zhang B, Boers M, for the American College of Rheumatology and the European League Against Rheumatism Committee to Define Remission for Clinical Trials. Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2010;62:108-17.
    • (2010) Arthritis Care Res (Hoboken) , vol.62 , pp. 108-117
    • Van Tuyl, L.H.1    Felson, D.T.2    Wells, G.3    Smolen, J.4    Zhang, B.5    Boers, M.6
  • 31
    • 37749041179 scopus 로고    scopus 로고
    • OMERACT: An international initiative to improve outcome measurement in rheumatology
    • Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
    • (2007) Trials , vol.8 , pp. 38
    • Tugwell, P.1    Boers, M.2    Brooks, P.3    Simon, L.4    Strand, V.5    Idzerda, L.6
  • 32
    • 53149147037 scopus 로고    scopus 로고
    • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    • Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008;59:1371-7.
    • (2008) Arthritis Rheum , vol.59 , pp. 1371-1377
    • Aletaha, D.1    Landewe, R.2    Karonitsch, T.3    Bathon, J.4    Boers, M.5    Bombardier, C.6
  • 33
    • 53149105544 scopus 로고    scopus 로고
    • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    • Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1360-1364
    • Aletaha, D.1    Landewe, R.2    Karonitsch, T.3    Bathon, J.4    Boers, M.5    Bombardier, C.6
  • 34
    • 0031990046 scopus 로고    scopus 로고
    • The OMERACT filter for Outcome Measures in Rheumatology
    • Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25: 198-9.
    • (1998) J Rheumatol , vol.25 , pp. 198-199
    • Boers, M.1    Brooks, P.2    Strand, C.V.3    Tugwell, P.4
  • 35
    • 34547431637 scopus 로고    scopus 로고
    • A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response
    • American College of Rheumatology Committee to Reevaluate Improvement Criteria
    • American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007;57:193-202.
    • (2007) Arthritis Rheum , vol.57 , pp. 193-202
  • 38
    • 2342658406 scopus 로고    scopus 로고
    • Radiographic, Clinical, and Functional Outcomes of Treatment with Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients with Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial
    • DOI 10.1002/art.20217
    • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.5 , pp. 1400-1411
    • Keystone, E.C.1    Kavanaugh, A.F.2    Sharp, J.T.3    Tannenbaum, H.4    Hua, Y.5    Teoh, L.S.6    Fischkoff, S.A.7    Chartash, E.K.8
  • 39
    • 0037231533 scopus 로고    scopus 로고
    • Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    • DOI 10.1002/art.10697
    • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
    • (2003) Arthritis and Rheumatism , vol.48 , Issue.1 , pp. 35-45
    • Weinblatt, M.E.1    Keystone, E.C.2    Furst, D.E.3    Moreland, L.W.4    Weisman, M.H.5    Birbara, C.A.6    Teoh, L.A.7    Fischkoff, S.A.8    Chartash, E.K.9
  • 40
    • 10744223002 scopus 로고    scopus 로고
    • Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial
    • DOI 10.1016/S0140-6736(04)15640-7, PII S0140673604156407
    • Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81. (Pubitemid 38296553)
    • (2004) Lancet , vol.363 , Issue.9410 , pp. 675-681
    • Klareskog, L.1    Van Der Heijde, D.2    De Jager, J.P.3    Gough, A.4    Kalden, J.5    Malaise, M.6    Martin Mola, E.7    Pavelka, K.8    Sany, J.9    Settas, L.10    Wajdula, J.11    Pedersen, R.12    Fatenejad, S.13    Sanda, M.14
  • 41
    • 31044442965 scopus 로고    scopus 로고
    • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    • DOI 10.1002/art.21519
    • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
    • (2006) Arthritis and Rheumatism , vol.54 , Issue.1 , pp. 26-37
    • Breedveld, F.C.1    Weisman, M.H.2    Kavanaugh, A.F.3    Cohen, S.B.4    Pavelka, K.5    Van Vollenhoven, R.6    Sharp, J.7    Perez, J.L.8    Spencer-Green, G.T.9
  • 43
    • 77953701043 scopus 로고    scopus 로고
    • Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials
    • Smolen JS, Aletaha D, Grisar JC, Stamm TA, Sharp JT. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010;69: 1058-64.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1058-1064
    • Smolen, J.S.1    Aletaha, D.2    Grisar, J.C.3    Stamm, T.A.4    Sharp, J.T.5
  • 44
    • 0015151774 scopus 로고
    • Methods of scoring the progression of radiologic changes in rheumatoid arthritis: Correlation of radiologic, clinical and laboratory abnormalities
    • Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
    • (1971) Arthritis Rheum , vol.14 , pp. 706-720
    • Sharp, J.T.1    Lidsky, M.D.2    Collins, L.C.3    Moreland, J.4
  • 45
    • 0024604643 scopus 로고
    • Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
    • Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8. (Pubitemid 19123055)
    • (1989) Lancet , vol.1 , Issue.8646 , pp. 1036-1038
    • Van der Heijde, D.M.1    Van Riel, P.L.2    Nuver-Zwart, I.H.3    Gribnau, F.W.4    Van de Putte, L.B.5
  • 47
    • 1542283763 scopus 로고    scopus 로고
    • Radiographic Progression Depicted by Probability Plots: Presenting Data with Optimal Use of Individual Values
    • DOI 10.1002/art.20204
    • Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum 2004;50:699-706. (Pubitemid 38326167)
    • (2004) Arthritis and Rheumatism , vol.50 , Issue.3 , pp. 699-706
    • Landewe, R.1    Van Der Heijde, D.2
  • 48
    • 17244364098 scopus 로고    scopus 로고
    • Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
    • DOI 10.1002/art.20982
    • Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy study. Arthritis Rheum 2005;52:1020-30. (Pubitemid 40530107)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.4 , pp. 1020-1030
    • Smolen, J.S.1    Han, C.2    Bala, M.3    Maini, R.N.4    Kalden, J.R.5    Van Der Heijde, D.6    Breedveld, F.C.7    Furst, D.E.8    Lipsky, P.E.9
  • 49
    • 67449124635 scopus 로고    scopus 로고
    • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and tumor necrosis factor blockade
    • for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group
    • Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumor necrosis factor blockade. Ann Rheum Dis 2009;68:823-7.
    • (2009) Ann Rheum Dis , vol.68 , pp. 823-827
    • Smolen, J.S.1    Han, C.2    Van Der Heijde, D.M.3    Emery, P.4    Bathon, J.M.5    Keystone, E.6
  • 50
    • 33750324355 scopus 로고    scopus 로고
    • Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes
    • DOI 10.1002/art.22143
    • Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25. (Pubitemid 44622081)
    • (2006) Arthritis and Rheumatism , vol.54 , Issue.10 , pp. 3119-3125
    • Landewe, R.1    Van Der Heijde, D.2    Klareskog, L.3    Van Vollenhoven, R.4    Fatenejad, S.5
  • 52
    • 33344470277 scopus 로고    scopus 로고
    • The definition and measurement of disease modification in inflammatory rheumatic diseases
    • DOI 10.1016/j.rdc.2005.09.005, PII S0889857X05000724, New Therapeutic in Rheumatic Diseases
    • Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9-44. (Pubitemid 43290588)
    • (2006) Rheumatic Disease Clinics of North America , vol.32 , Issue.1 , pp. 9-44
    • Aletaha, D.1    Smolen, J.S.2
  • 54
    • 76649091916 scopus 로고    scopus 로고
    • Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?
    • Linde L, Sorensen J, Ostergaard M, Horslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010;37:285-90.
    • (2010) J Rheumatol , vol.37 , pp. 285-290
    • Linde, L.1    Sorensen, J.2    Ostergaard, M.3    Horslev-Petersen, K.4    Hetland, M.L.5
  • 55
    • 78149471129 scopus 로고    scopus 로고
    • Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard
    • Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010;49:683-90.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 683-690
    • Balsa, A.1    De Miguel, E.2    Castillo, C.3    Peiteado, D.4    Martin-Mola, E.5
  • 56
    • 0028268568 scopus 로고
    • Reduced joint counts in controlled clinical trials in rheumatoid arthritis
    • Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994;37:470-5. (Pubitemid 24115932)
    • (1994) Arthritis and Rheumatism , vol.37 , Issue.4 , pp. 470-475
    • Fuchs, H.A.1    Pincus, T.2
  • 57
    • 0028813226 scopus 로고
    • Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity
    • Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
    • (1995) Arthritis Rheum , vol.38 , pp. 38-43
    • Smolen, J.S.1    Breedveld, F.C.2    Eberl, G.3    Jones, I.4    Leeming, M.5    Wylie, G.L.6
  • 59
    • 38749129727 scopus 로고    scopus 로고
    • Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: A pooled analysis of clinical trial results
    • DOI 10.1136/ard.2007.071415
    • Aletaha D, Strand V, Smolen JS, Ward MM. Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43. (Pubitemid 351183315)
    • (2008) Annals of the Rheumatic Diseases , vol.67 , Issue.2 , pp. 238-243
    • Aletaha, D.1    Strand, V.2    Smolen, J.S.3    Ward, M.M.4
  • 60
    • 0022627532 scopus 로고
    • Rheumatoid arthritis: Treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression
    • Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986;25:44-9. (Pubitemid 16156197)
    • (1986) British Journal of Rheumatology , vol.25 , Issue.1 , pp. 44-49
    • Dawes, P.T.1    Fowler, P.D.2    Clarke, S.3
  • 61
  • 62
  • 63
    • 34547535149 scopus 로고    scopus 로고
    • A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ)
    • DOI 10.1016/j.berh.2007.02.009, PII S1521694207000307
    • Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index Data (RAPID) scores on a Multidimensional Health Assessment Questionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007;21:789-804. (Pubitemid 47177167)
    • (2007) Best Practice and Research in Clinical Rheumatology , vol.21 , Issue.4 , pp. 789-804
    • Pincus, T.1    Yazici, Y.2    Bergman, M.3    Maclean, R.4    Harrington, T.5
  • 64
    • 33750979015 scopus 로고    scopus 로고
    • An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis
    • Pincus T, Chung C, Segurado OG, Amara I, Koch GG. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006;33: 2146-52. (Pubitemid 44749771)
    • (2006) Journal of Rheumatology , vol.33 , Issue.11 , pp. 2146-2152
    • Pincus, T.1    Chung, C.2    Segurado, O.G.3    Amara, I.4    Koch, G.G.5
  • 65
    • 34248650927 scopus 로고    scopus 로고
    • Patient perspective: Reasons and methods for measuring fatigue in rheumatoid arthritis
    • Kirwan JR, Hewlett S. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. J Rheumatol 2007; 34:1171-3. (Pubitemid 46774869)
    • (2007) Journal of Rheumatology , vol.34 , Issue.5 , pp. 1171-1173
    • Kirwan, J.R.1    Hewlett, S.2
  • 66
    • 33845608765 scopus 로고    scopus 로고
    • Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: Evidence from an imaging study may explain structural progression
    • DOI 10.1002/art.22190
    • Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006;54: 3761-73. (Pubitemid 44955876)
    • (2006) Arthritis and Rheumatism , vol.54 , Issue.12 , pp. 3761-3773
    • Brown, A.K.1    Quinn, M.A.2    Karim, Z.3    Conaghan, P.G.4    Peterfy, C.G.5    Hensor, E.6    Wakefield, R.J.7    O'Connor, P.J.8    Emery, P.9
  • 67
    • 54949135724 scopus 로고    scopus 로고
    • An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis
    • Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
    • (2008) Arthritis Rheum , vol.58 , pp. 2958-2967
    • Brown, A.K.1    Conaghan, P.G.2    Karim, Z.3    Quinn, M.A.4    Ikeda, K.5    Peterfy, C.G.6
  • 68
    • 0030749194 scopus 로고    scopus 로고
    • Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis
    • Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85. (Pubitemid 27320685)
    • (1997) Journal of Rheumatology , vol.24 , Issue.8 , pp. 1477-1485
    • Wolfe, F.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.